Clinical trial evaluating the effectiveness of biocompound IMMUNEPOTENT CRP in the third-molar extraction

Figures & data

Table 1. Intragroup comparisons of the percentage of swelling.

Group	Day 0	Day 3	Day 7
Ibuprofen	0%^c	3.26%ª	1.0%^b
IMMUNEPOTENT CRP	0%^d	2.61%^e	0.63%^f

Note: The percentage of swelling was determined by the method of Amin and Laskin [21].

^a p < 0.05 between day 0 and 3 in the ibuprofen group.

^b p < 0.001 between day 3 and 7 in the ibuprofen group.

^c p < 0.001 between day 0 and 7 in the ibuprofen group.

^d p < 0.05 between day 0 and 3 in the IMMUNEPOTENT CRP group.

^e p < 0.05 between day 3 and 7 in the IMMUNEPOTENT CRP group.

^f p < 0.05 between day 0 and 7 in the IMMUNEPOTENT CRP group.

Table 2. Comparison of the percentage of swelling between groups.

	Ibuprofen	IMMUNEPOTENT CRP	p Value^a
Day 0–0	0%	0%	–
Day 3–3	3.26%	2.61%	0.988
Day 7–7	1%	0.63%	0.447

Note: The percentage of swelling was calculated by the method of Amin and Laskin [21] at different times pre- and post-operatively.

^a p < 0.05 was considered significant.

Table 3. Saliva cytokines production in patients given ibuprofen or IMMUNEPOTENT CRP.

	Ibuprofen (days)			IMMUNEPOTENT CRP (days)
Cytokines (pg/mL)	0	3	7	0	3	7
INF	0.92 ± 0.24	4.40 ± 1.94	1.46 ± 0.46	1.4 ± 0.52	2.64 ± 0.94	3.56 ± 1.54
TNF	3.95 ± 2.22	8.33 ± 4.77	9.64 ± 4.05	3.91 ± 1.40	5.75 ± 2.54	11.78 ± 6.49
IL-2	0.41 ± 0.26	0.64 ± 0.38	0.383 ± 0.17	0.46 ± 0.19	0.36 ± 0.13	0.60 ± 0.36
IL-4	0.14 ± 0.11	0.20 ± 0.15	0.09 ± 0.03	0.12 ± 0.08	0.09 ± 0.06	0.18 ± 0.11
IL-6	24.02 ± 17.24	438.47 ± 164.32	199.30 ± 39.18	46.81 ± 18.95	355.22 ± 161.73	468.22 ±160.63
IL-10	0.14 ± 0.11	0.99 ± 0.43	0.63 ± 0.36	0.11 ± 0.09	0.28 ± 0.16	0.81 ± 0.43

Note: Saliva cytokines production was determined by flow cytometry.

There were no statistically significant differences between groups (p > 0.05).

Amin MM, Laskin DM. Prophylactic use of indomethacin for prevention of post-surgical removal of impacted lower third molar. Al-Rafidain Dent. 1983;6:114–121.

 Google Scholar